Medication info
Olmesartan Medoxomil and Rosuvastatin Tablets 20/5 mg

Olmesartan Medoxomil and Rosuvastatin Tablets 20/5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
White or yellowish round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/Alu-Alu)x3]
Approval status
Active

MFDS item code 202100100 · Approved 2021.01.06

Summary

Main use
Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to elderly patients aged 65 years or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use of this medicine is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
The safety and efficacy of this medicine in children under 18 years of age have not been established.

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of premature coronary heart disease
View approved original text

This medication is used for patients who need to take both olmesartan medoxomil and rosuvastatin at the same time. Olmesartan medoxomil helps treat essential hypertension. Meanwhile, rosuvastatin is used as an adjunctive treatment in cases of hypercholesterolemia and mixed hyperlipidemia where dietary changes are ineffective, and it is particularly effective in treating primary dyslipidemia and familial hypercholesterolemia. Additionally, rosuvastatin lowers total cholesterol and LDL cholesterol levels, which helps delay the progression of atherosclerosis and reduces the risk of stroke, myocardial infarction, and arterial revascularization in certain cardiovascular disease risk groups. Therefore, this medication is used to manage both hypertension and dyslipidemia to improve cardiovascular health.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is necessary when this medicine is administered to elderly patients aged 65 years or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use of this medicine is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

The safety and efficacy of this medicine in children under 18 years of age have not been established.

Precautions

This medication poses a risk of severe harm or death to the fetus and newborns if administered to women in the second and third trimesters of pregnancy, so use should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to patients with known allergies to this medication or its components, pregnant women or women who may become pregnant, nursing mothers, patients with severely impaired kidney function, patients with severe liver impairment, patients with biliary obstruction, and patients with myopathy. When administering to patients with reduced blood volume or sodium, there is a possibility of hypotension, so caution is necessary, and renal function should be periodically monitored as there may be changes in renal function. This medication may cause hyperkalemia, so serum potassium levels should be regularly monitored, and caution is required when engaging in hazardous activities such as operating dangerous machinery or driving, as dizziness may occur. This medication may affect liver function; therefore, liver function tests should be performed before and during treatment, and greater caution is required for patients with a history of liver disease. If symptoms of muscle pain, muscle weakness, or myopathy occur, it is essential to immediately notify healthcare professionals and undergo testing, and in severe cases, use should be discontinued. This medication may interact with other drugs, so it is crucial to inform healthcare providers of any current medications, especially when used concurrently with potassium-sparing diuretics, lithium, nonsteroidal anti-inflammatory drugs, certain antibiotics, and antifungals. Women who are pregnant or planning to become pregnant should avoid using this medication and use appropriate contraception. Nursing mothers should also avoid using this medication or discontinue breastfeeding. Safety and efficacy in children under 18 years have not been established, hence it is recommended against use in this population. For elderly patients, dosage adjustment may be necessary, and in the case of overdose, symptoms such as hypotension and palpitations may occur, requiring immediate visit to a healthcare facility. This medication should be stored out of reach of children, and it is safest not to transfer it to other containers.

Side effects

Increased ALT, increased AST, increased serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, dizziness, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, angioedema, anaphylaxis, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, increased blood pressure, back pain, increased serum creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reaction including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it must be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 degree and 30 degrees Celsius. Storing it correctly ensures the medication's effectiveness and safety.

Appearance and packaging

Appearance

White or yellowish round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/Alu-Alu)x3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.